A Nanotechnology Patch for Early-Stage Oral Cancer
Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)
This project supports a late-stage clinical trial for a new topical patch designed to treat early-stage oral cancer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Privo Technologies, LLC NIH-funded |
| Lab location | 1 site (Peabody, United States) |
| Project ID | NIH-11116997 on NIH RePORTER |
What this research studies
This grant focuses on a Phase 3 clinical trial for PRV111, a topical chemotherapy patch for Carcinoma in Situ of the Oral Cavity, also known as Stage 0 oral cancer. Current treatments for oral cancer often involve extensive surgery, which can lead to severe and permanent side effects like speech impairment, difficulty swallowing, and facial disfigurement. This new patch aims to deliver a chemotherapy drug directly to the tumor using tiny nanoparticles, potentially avoiding the need for such invasive procedures. The patch is designed to stick to the affected area and release the medication locally, offering a less invasive treatment option for patients.
Who could benefit from this research
Good fit: Ideal candidates would be patients diagnosed with Carcinoma in Situ of the Oral Cavity, also known as Stage 0 oral cancer.
Not a fit: Patients with more advanced stages of oral cancer or other types of cancer would likely not benefit from this specific topical treatment.
Why it matters
Potential benefit: If successful, this treatment could offer patients with early oral cancer a less invasive option that avoids the devastating side effects of surgery, significantly improving their quality of life.
How similar studies have performed: This nanotechnology-based topical delivery system is a novel approach for oral cancer, building upon the established use of chemotherapy drugs.
Where this research is happening
Peabody, United States
- Privo Technologies, LLC — Peabody, United States (Active)
Researchers
- Principal investigator: Goldberg, Manijeh N — Privo Technologies, LLC
- Study coordinator: Goldberg, Manijeh N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.